Muhamed Baljevic, MD

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

Muhamed Baljevic, MD, discusses the consideration of patient comorbidities and preferences during treatment selection in newly diagnosed myeloma.

Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma.

Muhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.

Muhamed Baljevic, MD, discusses the FDA approval of isatuximab-irfc in combination with pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma.